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ABSTRACT
Introduction: Cost assessment modelling
(CAM) of treatments in highly active relapsing
multiple sclerosis was conducted.
Methods: The CAM was developed using the
R programming language. The PICOSTEPS
health technology assessment framework was
applied in the CAM. Modelled patients were 280
adults with highly active relapsing multiple
sclerosis eligible for disease-modifying treat-
ment. Intervention was cladribine tablets, a new
and reimbursed oral treatment for highly active
relapsing multiple sclerosis in Finland. Com-
parators included fingolimod, the most used
oral reimbursed treatment for the highly active
disease, and natalizumab, the most used intra-
venous treatment, and a treatment mix (80%
use fingolimod, 20% use natalizumab) in Fin-
land. Outcomes presented expected annual and
cumulative drug-associated costs in the overall
population and per patient. Setting was mod-
elled public specialist care in Finland. Time was
set to 4 years, without discounting. Effects cov-
ered expected drug-associated costs (screening,
acquisition, administration, monitoring,
adverse events, travelling, productivity). Per-
spective was a limited societal perspective.
Sensitivity analyses regarding all PICOSTEPS
components were conducted.
Results: Cladribine tablets were projected to be
cost saving in comparison to fingolimod,
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natalizumab and treatment mix. The respective
modelled savings were €4,598,742, €16,249,701
and €6,928,934 in the overall population, and
€16,424, €58,035 and €24,746 per patient,
respectively, during the 4 years. The most
important cost driver was drug costs, repre-
senting 96.3%, 96.0% and 83.4% of modelled
costs associated with cladribine tablets, fin-
golimod and natalizumab, respectively.
Cladribine tablets sustained their affordability
in the sensitivity analyses. From the perspective
of health care payer, cladribine tablets’ savings
were projected to be €4,514,509, €15,145,366
and €6,640,680 in the overall population, and
€16,123, €54,091 and €23,717 per patient in
comparison to fingolimod, natalizumab and
treatment mix, respectively.
Conclusion: Based on the CAM, cladribine
tablets were projected to robustly save modelled
drug-associated costs in comparison to fin-
golimod, natalizumab and their mix in Finland.
Keywords: Cladribine tablets; Cost;
Fingolimod; Multiple sclerosis; Natalizumab;
Productivity; Travelling
Key Summary Points
Why carry out this study?
Multiple sclerosis results in considerable
financial burden.
Research of costs in highly active multiple
sclerosis is scarce, especially in the Finnish
setting.
Drug-related costs of three multiple
sclerosis treatments and a treatment mix
of fingolimod and natalizumab in highly
active relapsing multiple sclerosis were
modelled over 4 years in Finland.
What was learned from the study?
Drug-related costs of cladribine tablets
were €71,413 per patient. The respective
per-patient costs for fingolimod,
natalizumab and treatment mix were
€16,424; €58,035; and €24,746 higher,
respectively.
Cladribine tablets were robustly projected
to be a cost-saving treatment option
compared to fingolimod, natalizumab and
their treatment mix in the Finnish setting.
INTRODUCTION
Multiple sclerosis (MS) is an immune-mediated
disorder of the central nervous system with a
wide heterogeneity in the clinical course. Most
patients are classified as having a relaps-
ing–remitting MS (RRMS) [1], which is further
classified as active or highly active, based on the
relapse rate and magnetic resonance imaging
(MRI) findings [2]. Approximately 4–14% of all
MS patients, depending on the definition used,
already have a highly active disease course from
the onset [3]. During the disease trajectory, this
subgroup of patients is marked by a rapid
accumulation of functional deficits and MRI
activity, despite treatment with one or more
disease-modifying drugs (DMDs) [4].
MS is a leading cause of disability in adults,
and requires lifelong treatment [5, 6]. The
average time from MS onset to death is 35 years
[7]. There is no cure for MS, but DMDs prevent
relapses and delay disease progression [8].
According to the Finnish treatment guideli-
nes, patients eligible to receive a DMD for
highly active disease need to show one relapse
in the previous year and at least one T1
gadolinium-enhancing lesion or 9 or more T2
lesions while on therapy with a DMD, or two or
more relapses in the previous year, whether or
not on DMD [9]. Three approved DMDs for the
highly active disease are used in Finland:
cladribine tablets, fingolimod and natalizumab
[10–12]. Cladribine tablets are approved for use
for the treatment of adult patients with highly
active relapsing MS, including RRMS, and
relapsing secondary progressive MS populations
[10].
Finland is a high-risk MS region with a
prevalence of 280/100,000 in southwest parts of
the country [13], and a nationwide prevalence
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estimate between 10,000 and 11,000 patients,
corresponding to a crude prevalence of
180–200/100,000 [14]. The estimated annual
economic burden of MS in Finland using a
bottom–up approach of costing was €46,994 per
patient on average and increasing from €10,835
to €109,901 in parallel with advancing disability
[15]. Based on a modelled economic evaluation
of RRMS patients who have initiated a DMD,
effective and reasonably priced DMDs may
compensate for various RRMS-related costs in a
15-year time horizon [16]. The impact of MS
medication costs on overall healthcare systems
has been assessed by per-member per-period
costs, where MS represents the fourth most
expensive therapy class following inflammatory
conditions, diabetes and cancer [17]. In Finland,
the estimated proportion of total costs
attributable to DMDs is high over 1-year [15]
and moderately high (11–18%, depending on
DMD) over 15-year [16] time horizons among
RRMS patients who have initiated DMD and
were valid for a publicly reimbursed DMD.
The costs and cost-effectiveness of DMDs
indicated for highly active disease in Finland
have not previously been published. In foreign
settings and modelled comparisons, cladribine
tablets have been observed to be dominant (i.e.
lower cost and higher effectiveness) in various
settings: compared to fingolimod in Spanish
patients with highly active relapsing disease
[18], compared to alemtuzumab and natal-
izumab in English patients with highly active
RRMS [19], and compared to alemtuzumab and
fingolimod in patients with highly active RRMS
as well as compared to natalizumab in patients
with rapidly evolving severe disease in the
Dutch setting [20]. A cost assessment model
(CAM) was developed to project the costs of
DMDs for highly active disease in Finland.
METHODS
The CAM was developed with the programming
language R to project drug-related costs of
selected highly active MS therapies based on
input parameters described below. The CAM
approach was developed for easy and safe esti-
mation of costs over time. To ensure the
coverage of important features, PICOSTEPS
principle [16, 21–23] was applied in the CAM
dashboard.
PICOSTEPS (Patients–Intervention–Com-
parators–Outcomes–Setting–Time–Effects–Per-
spective–Sensitivity analysis) is a framework for
reporting health economic studies. It covers the
essential parts of health economic evaluations
in their order of importance [16, 21, 23];
(Table 1). PICOSTEPS has been used in multiple
Finnish health economic studies and in a Cur-
rent Care guideline [16, 21, 23].
Patients
The yearly number of Finnish relapsing MS
patients with highly active disease, who initiate
DMD or switch from another DMD, is estimated
to be approximately 280, based on Finnish
reimbursement statistics. Based on this estima-
tion, the size of the modelled patient popula-
tion was chosen to be 280.
Patients were modelled to have cladribine
tablets 10 mg (cumulative dose 3.5 mg/kg over
2 years) (intervention), or alternatively (1) fin-
golimod 0.5 mg, (2) natalizumab 300 mg or (3)
a treatment mix consisting of 80% patients
using fingolimod and 20% of patients using
natalizumab based on the Finnish clinical
practice, and their similar patient populations
defined in their summaries of product charac-
teristics [10–12] (comparators). Highly active
disease patients are defined by clinical or
imaging features according to the Finnish
treatment guidelines and reimbursement crite-
ria [9, 24, 25]. Seventy-two percent of patients
were women in the model input [16]. Patients
were assumed to stay alive until the end of fol-
low-up (4 years).
The analysis was based on modelling, and
the data utilized were obtained from previously
conducted studies. The study did not include
any new studies with human participants or
animals performed by any of the authors. Thus,
the study was not registered with any clinical
trial database.
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Table 1 PICOSTEPS applied in the highly active relapsing MS cost assessment model (CAM) input
PICOSTEPS
[16, 21–23]
Deﬁnition Respective sources
P: patients Disease: highly active relapsing MS [9–12, 24, 25]
Feasible MS population in Finland: 280 patients Sales statistics estimate for dynamic
population
Gender: 72% women [16]
Weight: 86.4 kg male, 72.4 kg female [26]
I: intervention Cladribine tablets [10]
C:
comparators
Fingolimod and natalizumab, and a treatment mix (80% use
ﬁngolimod, 20% use natalizumab)
[11], Finnish clinical practice for
natalizumab, sales statistics for the
treatment mix
O: outcomes Expected annual and cumulative drug-associated costs, cost
dispersion
Rationale: [27, 28]
S: setting Modelled specialist care in Finland [10–12]; clinical practice
T: time Four years drug acquisition costs at June 2019 values, hospital
district tariffs at 2019 values, other costs at year 2018
values, no discounting
Rationale: [27, 28]
E: effects Drug-associated costs (screening, acquisition, administration,
monitoring, adverse events, travelling, productivity)
SmPCs [10–12] or clinical practice; see
Tables 2 and 3
P: perspective Drug-related costs (partially societal) Logical assumption
S: sensitivity
analyses
P: 50% or 90% female Assumption
P: average age 36 years [16]
P: age–weight distribution [26]
I: adherence decreases 10% each year As above, assumption
C: adherence decreases 10% each year Assumption
S: no screening Assumption
T: 3-year results Assumption
E: ﬁngolimod use based on clinical practice Finnish clinical practice (ﬁngolimod)
E: natalizumab use based on Tysabri SmPC [12]
E: natalizumab administration based on Finnish price tariffs [29, 30]
E: All cost inputs ±20% Assumption
E: ﬁngolimod used after cladribine tablets (sequential
approach)
Assumption (risks: [31])
P: direct costs [32]
P: direct costs without travelling costs [32]
P: drug costs alone [32]
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Table 3 Unit costs utilized in the analysis
Cost driver Expense Cost (€) Reference
Drug acquisition Cladribine 10 mg, 1 tbl 2433.69 FMT 06/19 [34]
Cladribine 10 mg, 4 tbl 9624.82 FMT 06/19 [34]
Cladribine 10 mg, 6 tbl 14,418.91 FMT 06/19 [34]
Fingolimod 0.5 mg 7tbl 427.62 FMT 06/19 [34]
Fingolimod 0.5 mg 28tbl 1612.99 FMT 06/19 [34]
Natalizumab 300 mg 2250.00 FMT 06/19 [34]
Drug
administration
Natalizumab NaCl for infusion 0.87 FMT 06/19 [34]
Natalizumab infusion administratione 309.82 [38] indexed to 2018 valuea
Monitoring Electrocardiogram (EKG), 6 hf 587.00 [30]
Full blood count, FBC 4.60 [35]
JC virus antibodies 70.00 [35]
Latent infections 120.53 [35]
Magnetic resonance imaging (MRI) of head and
spinee
320.00 [30]
Ophthalmologic examinatione 215.60 [36] indexed to 2018 valuea
Transaminases, bilirubin 4.00 [35]
Varicella zoster (VZ) antibodies 20.00 [35]
VZ vaccinationd 203.68 [36] indexed to 2018 valuea/FMT
6/2019 [34]
Test takingd 5.52 [37] indexed to 2018 valuea
Adverse event Abnormal laboratory ﬁndings related to liver
functiond
96.26b [36] indexed to 2018 valuea, VSSHP
[35]
Lymphopeniad 226.83c [36] indexed to 2018 valuea, [35]
Travelling Primary care 7.40 [37] indexed to 2018 valuea
Secondary care 37.80 [37] indexed to 2018 valuea
Productivity loss Primary care (1/4 day) 64.24 [42] indexed to 2018 valuea
Secondary care (half a day) 128.48 [42] indexed to 2018 valuea
Full day 256.96 [42] indexed to 2018 valuea
FMT Finnish Medicines Tariff
a Ofﬁcial Statistics of Finland [41]
b Blood test, specialist paper consultation, specialist telephone consultation, 5% of patients an additional specialist visit and
upper stomach ultrasound
c Lymphocytes differential count, specialist paper consultation, specialist telephone consultation
d Productivity loss and travelling cost for this procedure estimated to be  day
e Productivity loss and travelling cost for this procedure estimated to be  day
f Productivity loss and travelling cost for this procedure estimated to be full day
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Resources and Costs
The primary focus on analytical perspective was
on drug-related costs. The perspective was par-
tially societal, considering direct drug-related
costs, such as drug acquisition and administra-
tion costs, monitoring and adverse events (AEs),
as well as indirect drug-related costs such as
productivity loss (absenteeism) and travelling
costs related to the health care resources used.
This perspective considers the direct costs to the
same extent as the Finnish medicines agency
(Fimea) guidelines on the evaluation of hospital
products [33].
Drug-associated screening, acquisition,
administration (also including infusions where
relevant), monitoring, AEs, travelling, and pro-
ductivity costs (Tables 2 and 3) were based on
Finnish practices, sources and price tariffs
[16, 29, 30, 34–38], and SmPCs [10–12]. Official
Finnish list prices of drugs from June 2019 were
applied. No treatment pauses or discontinua-
tions were permitted in the base case, but their
impact was tested in the sensitivity analyses.
Cladribine tablets were used according to the
Mavenclad SmPC, i.e. two annual treatment
courses giving a cumulative dose of 3.5 mg/kg
over 2 years and applying 86.4 kg average
weight for men and 72.4 kg average weight for
women (average adult weight in nationally
representative FinTerveys study [26]). In sensi-
tivity analyses, age and age–weight distributions
were applied to inform the dosing of cladribine
tablets [26]. In addition, 24% of cladribine
tablets users were assumed to initiate fin-
golimod on the fourth year, based on the pro-
portion of relapse-free patients (76%) in a
CLARITY extension study [31].
Conservatively (i.e. not benefitting cladrib-
ine tablets), fingolimod users collected a
7-tablet pack and 13 28-tablet packs from a
community pharmacy during the first year of
their treatment, and 13 28-tablet packs annually
as per label [11], which is the most affordable
treatment practice for fingolimod. In the sensi-
tivity analysis, 14 28-tablet packs were assumed
to be collected from a community pharmacy
during the first year based on the Finnish clin-
ical practice. Since cladribine tablets and fin-
golimod have restricted reimbursements in
Finland, and they are used in an outpatient
setting [24, 25], the retail prices of Finnish
medicine tariff [34] excluding value added tax
(VAT 10%) were used.
Likewise, natalizumab was conservatively
assumed to be administered 12 times per year in
a hospital setting based on the Finnish clinical
practice and the most affordable treatment
practice for natalizumab. In the sensitivity
analysis, 14 natalizumab infusions took place
during the first year and 13 during subsequent
years based on the 28-day dosing interval
described in the SmPC [12]. The official whole-
sale price was used for hospital-administered
natalizumab [34] and its administration cost
was accrued from a Finnish study [38]. In the
sensitivity analyses, two other sources for the
administration costs were applied. The admin-
istration costs (€934.50 and €373.00) were based
on a drug-inclusive administration cost
(€2623.00) found in the price tariff of the
Hospital District of Pirkanmaa, Finland, [29] of
which the cost of administration was derived
from the total cost by subtracting (1) the official
wholesale price of natalizumab dose (€2250.00)
and (2) the average drug price of natalizumab
(€1688.50) found in the price tariff of the hos-
pital district of Uusimaa, Finland [30].
Statistical significance related to risk assess-
ment can be impacted, for example, by assumed
statistical power, accrued sample size and fol-
low-up time. Thus, the AEs for CAM were
accounted for by annualizing the AE probabili-
ties [43] of clinical trials [39, 40, 44], and by
applying an inclusion threshold of C4%
between the active treatment and placebo in
the AE probability [16].
Finally, analytical perspective can have a
considerable impact on the outcomes of health
economic evaluation (e.g. [16, 21, 45–47]). In
this modelled assessment, productivity costs
were based on absenteeism due to drug-associ-
ated screening, infusions, monitoring, AEs, and
travelling. Absenteeism was valued based on the
human capital approach using a Finnish valua-
tion. Sensitivity analyses covered different
costing perspectives.
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Outcomes
Primary outcomes included undiscounted
modelled annual and cumulative treatment-re-
lated costs presented in the overall population
of 280 patients and per patient. The cost drivers
were defined in year 2018 (unit costs in older
than year 2018 values were indexed to the year
2018 real value) and 2019 values. Annual costs
were calculated by adding up the cost drivers for
each treatment per year, and the cumulative
costs by adding up the annual costs and the
screening costs for each treatment.
Extensive deterministic sensitivity analyses
were conducted for all PICOSTEPS inputs.
RESULTS
Overall, the intervention (cladribine tablets)
were projected to reduce the expected drug
associated costs in comparison to the com-
parators (fingolimod, natalizumab, treatment
mix) during the 4-year treatment period and
associated screening (Figs. 1, 2; Tables 4, 5).
Annual Costs
Annual modelled costs during the 4-year treat-
ment period were relatively stable for the com-
parators, but not for cladribine tablets (Figs. 1,
2; Tables 4, 5). Cladribine tablets are acquired in
Fig. 1 Annual acquisition costs per patient
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the first 2 years, whereas the comparators are
acquired continuously.
The modelled total screening costs of
cladribine tablets were €619 per patient and
€173,303 in the overall population. The mod-
elled total screening costs of fingolimod, natal-
izumab, and treatment mix were €502, €509,
and €504 per patient and €140,674, €142,449,
and €141,029, respectively, in the overall
population.
In the first year, the modelled costs of
cladribine tablets were €35,007 per patient and
€9,802,041 in the population. In comparison,
the modelled costs of fingolimod, natalizumab,
and the treatment mix were €23,034, €32,129,
and €24,853 per patient and €6,449,493,
€8,996,169, and €6,958,828 in the overall pop-
ulation, respectively.
The modelled costs in the second year with
cladribine tablets were €34,927 per patient and
€9,779,547 in the overall population. In com-
parison, the second-year modelled costs of fin-
golimod, natalizumab, and the treatment mix
were €21,434, €32,129, and €23,573 per patient
and €6,001,421, €8,996,169, and €6,600,370 in
the overall population, respectively.
During the third and fourth years, the mod-
elled drug-associated costs remained unchanged
in both years for each treatment. Because
cladribine tablets had no drug-acquisition costs
Fig. 2 Drug-associated screening costs, and annual monitoring, administration, AEs, travelling, and productivity costs per
patient. S = Screening
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Table 4 Drug-associated costs (€) per patient
Drug Screening Year 1 Year 2 Year 3 Year 4 Sum Difference to
cladribine
Cladribine
Adverse event 0 24 24 24 24 95 NA
Drug acquisition 0 34,376 34,376 0 0 68,753 NA
Monitoring 501 461 350 320 320 1952 NA
Productivity loss 71 93 116 48 48 376 NA
Travelling 46 53 61 39 39 238 NA
Sum 619 35,007 34,927 430 430 71,413 NA
Fingolimod
Adverse event 0 15 15 15 15 58 - 37
Drug acquisition 0 21,396 20,969 20,969 20,969 84,303 15,550
Monitoring 385 1175 334 334 334 2562 610
Productivity loss 71 297 70 70 70 579 203
Travelling 46 151 46 46 46 335 98
Sum 502 23,034 21,434 21,434 21,434 87,837 16,424
Natalizumab
Adverse event 0 0 0 0 0 0 - 95
Drug acquisition 0 27,000 27,000 27,000 27,000 108,000 39,247
Drug administration 0 3728 3728 3728 3728 14,913 14,913
Monitoring 396 320 320 471 471 1978 25
Productivity loss 68 590 590 635 635 2517 2141
Travelling 45 491 491 506 506 2040 1803
Sum 509 32,129 32,129 32,340 32,340 129,448 58,035
Treatment mix
Adverse event 0 12 12 12 12 47 - 48
Drug acquisition 0 22,517 22,175 22,175 22,175 89,042 20,290
Drug administration 0 746 746 746 746 2983 2983
Monitoring 387 1004 331 362 362 2445 493
Productivity loss 71 355 174 183 183 967 591
Travelling 46 219 135 138 138 676 439
Sum 504 24,853 23,573 23,615 23,615 96,159 24,746
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Table 5 Drug-associated costs (€) in the population
Drugs and cost
drivers
Screening Year 1 Year 2 Year 3 Year 4 Sum Difference to
cladribine
Cladribine
Adverse event 0 6637 6637 6637 6637 26,548 NA
Drug acquisition 0 9,625,384 9,625,384 0 0 19,250,767 NA
Monitoring 140,337 129,016 98,102 89,600 89,600 546,655 NA
Productivity loss 20,001 26,062 32,411 13,363 13,363 105,200 NA
Travelling 12,965 14,942 17,013 10,799 10,799 66,519 NA
Sum 173,303 9,802,041 9,779,547 120,399 120,399 19,995,689 NA
Fingolimod
Adverse event 0 4074 4074 4074 4074 16,295 - 10,253
Drug acquisition 0 5,991,017 5,871,284 5,871,284 5,871,284 23,604,868 4,354,101
Monitoring 107,708 328,946 93,554 93,554 93,554 717,316 170,662
Productivity loss 20,001 83,153 19,657 19,657 19,657 162,125 56,925
Travelling 12,965 42,304 12,853 12,853 12,853 93,826 27,308
Sum 140,674 6,449,493 6,001,421 6,001,421 6,001,421 24,594,430 4,598,742
Natalizumab
Adverse event 0 0 0 0 0 0 - 26,548
Drug acquisition 0 7,560,000 7,560,000 7,560,000 7,560,000 30,240,000 10,989,233
Drug administration 0 1,043,902 1,043,902 1,043,902 1,043,902 4,175,607 4,175,607
Monitoring 110,746 89,600 89,600 131,892 131,892 553,730 7075
Productivity loss 19,049 165,089 165,089 177,788 177,788 704,801 599,602
Travelling 12,654 137,578 137,578 141,721 141,721 571,252 504,733
Sum 142,449 8,996,169 8,996,169 9,055,302 9,055,302 36,245,390 16,249,701
Treatment mix
Adverse event 0 3259 3259 3259 3259 13,036 - 13,512
Drug acquisition 0 6,304,814 6,209,027 6,209,027 6,209,027 24,931,894 5,681,127
Drug administration 0 208,780 208,780 208,780 208,780 835,121 835,121
Monitoring 108,316 281,077 92,763 101,221 101,221 684,599 137,944
Productivity loss 19,811 99,540 48,743 51,283 51,283 270,660 165,460
Travelling 12,903 61,359 37,798 38,626 38,626 189,312 122,793
Sum 141,029 6,958,828 6,600,370 6,612,197 6,612,197 26,924,622 6,928,934
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in the third and fourth years, the modelled costs
of cladribine tablets plummeted by 99% to €430
per patient and €120,399 in the overall popu-
lation per year. The modelled costs of fin-
golimod remained the same as during the
second year. Modelled natalizumab costs
increased by 0.7% compared to the first and
second years and rose to €32,340 per patient
and to €9,055,302 in the overall population per
year, due to JC virus antibody testing and
associated blood sampling, travelling, and pro-
ductivity loss. The increase of modelled natal-
izumab costs also increased the total cost of the
treatment mix compared to the second year of
the treatment period by 0.2% to €23,615 per
patient and to €6,612,197 in the overall popu-
lation per year.
Over the 4-year treatment period, the aver-
age modelled annual costs were €17,699 for
cladribine tablets, €21,834 for fingolimod,
€32,235 for natalizumab and €23,914 for treat-
ment mix. Consequently, cladribine tablets
were projected to save 19–45% on the average
annual drug-associated costs in comparison to
the comparators.
Cumulative Costs
During the 4-year treatment period, cladribine
tablets were found to have lower costs than the
comparators in terms of cumulative modelled
costs (Tables 4, 5). The modelled cumulative
costs for the 4 years including screening were:
cladribine tablets €71,413 per patient and
€19,995,689 in the overall population of 280
patients, fingolimod €87,837 per patient and
€24,594,430 in the overall population, natal-
izumab €129,448 per patient and €36,245,390
in the overall population, and treatment mix
€96,159 per patient and €26,924,622 in the
overall population. The largest difference for
the cumulative costs in the overall population
compared to cladribine tablets was with natal-
izumab (€58,035 per patient, €16,249,701 in the
overall population; 81% difference in the
cumulative costs), the second largest with the
treatment mix (€24,746 per patient, €6,928,934
in the overall population; 35% difference), and
the smallest difference was with fingolimod
(€16,424 per patient, €4,598,742 in the overall
population; 23% difference).
Comparison of modelled cost drivers between
the treatments demonstrates the comparative
affordability of cladribine tablets (Tables 4, 5).
The modelled cost of cladribine tablets’ drug
acquisition, monitoring, productivity loss, and
travelling was the most affordable. The modelled
cost of AEs with natalizumab was the most
affordable. Because cladribine tablets and fin-
golimod are used orally without administration
in the health care setting, only natalizumab and
the treatment mix have administration costs.
Tables 4 and 5 show the differences between the
treatments per cost driver.
The most important cost drivers were drug-
acquisition costs. The drug-acquisition costs
represented 96.3%, 96.0%, 83.4% and 92.6% of
modelled costs associated with cladribine
tablets, fingolimod, natalizumab and treatment
mix, respectively.
Sensitivity Analyses
Cladribine tablets remained affordable in the
extensive sensitivity analyses (Tables 6, 7) with
the 4-year time horizon.
The only analysis scenario where cladribine
tablets were not the most affordable treatment
alternative was the time horizon of 3 years,
where fingolimod was €4580 less costly per
patient and €1,282,280 less costly in the overall
population and compared to cladribine tablets.
Cladribine tablets remained affordable after
assuming subsequent treatment with fin-
golimod in the fourth year for a proportion
(24%) of patients. The modelled cost of
cladribine tablets was €76,959 per patient and
€21,548,433 in the overall population. The
savings were €10,879, €52,489, and €19,201 per
patient and €3,045,997, €14,696,957, and
€5,376,189 in the overall population in com-
parison to fingolimod, natalizumab, and treat-
ment mix, respectively.
From the perspective of health care payer
alone, cladribine tablets’ modelled savings were
projected to be €16,123, €54,091 and €23,717
per patient and €4,514,509, €15,145,366 and
€6,640,680 in the overall population in
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comparison to fingolimod, natalizumab and
treatment mix, respectively.
DISCUSSION
Our CAM-based modelled study of DMD-asso-
ciated costs demonstrates that cladribine tablets
are a cost-saving treatment alternative for
patients with highly active relapsing MS com-
pared to fingolimod and natalizumab in the
Finnish setting. The average 4-year modelled
cost difference of drug-associated costs was
€16,424 per patient compared to fingolimod,
€58,035 compared to natalizumab, and €24,746
compared to treatment mix. In the overall
Table 6 Per-patient results of the sensitivity analyses covering all PICOSTEPS components (€)
Analysis Cladribine
tablets
Fingolimod
(difference to
cladribine tablets)
Natalizumab
(difference to
cladribine tablets)
Treatment mix
(difference to
cladribine tablets)
Base case 71,413 16,424 58,035 24,746
50% of patients women 72,468 15,369 56,980 23,691
90% of patients women 70,550 17,287 58,898 25,609
Age of the population 36 years 72,585 15,252 56,863 23,574
Patient weight based on Finnish real-life
distribution instead of on an average
72,065 15,772 57,382 24,094
Annual adherence drop 10% after 1st
year
67,976 7280 43,035 14,431
No screening costs 70,794 16,541 58,145 24,861
Time horizon 3 years 70,983 - 4580 26,124 1561
Fingolimod utilization: 14 28-tablet
packs during the 1st year, 13 packs
thereafter
71,413 17,609 58,035 25,694
Natalizumab utilization: 14
administrations during the 1st year,
13 administrations thereafter
71,413 16,424 71,254 27,390
Cost of natalizumab administration
€934.50
71,413 16,424 88,020 30,743
Cost of natalizumab administration
€373.00
71,413 16,424 61,068 25,353
All cost inputs -20% 57,131 13,139 46,428 19,797
All cost inputs ?20% 85,696 19,709 69,642 29,695
24% of cladribine users assumed to
switch to ﬁngolimod on the fourth
year
76,959 10,879 52,489 19,201
Direct costs only 71,037 16,221 55,893 24,155
Direct costs only, no travelling costs 70,800 16,123 54,091 23,717
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population of 280 patients, the respective drug-
associated cost differences to cladribine tablets
were €4,598,742, €16,249,701, and €6,928,934.
The most important cost drivers of modelling
were drug-acquisition costs, which accrued
96.3% of the total costs for cladribine tablets,
96.0% for fingolimod, 83.4% for natalizumab,
and 92.6% for treatment mix, and drug
administration for natalizumab, which was the
only intravenous drug in the study.
Cladribine tablets were also cost saving in all
sensitivity analyses with a 4-year time horizon,
even when assuming a sequential approach.
These findings are supported by cost estimates
from other settings [18–20]. The only exception
was with the 3-year time horizon, in which
Table 7 Per-population results of the sensitivity analysis covering all PICOSTEPS components (€)
Analysis Cladribine
tablets
Fingolimod
(difference to
cladribine tablets)
Natalizumab
(difference to
cladribine tablets)
Treatment mix
(difference to
cladribine tablets)
Base case 19,995,689 4,598,742 16,249,701 6,928,934
50% of patients women 20,291,004 4,303,427 15,954,386 6,633,619
90% of patients women 19,754,067 4,840,363 16,491,322 7,170,555
Age of the population 36 years 20,323,777 4,270,654 15,921,613 6,600,845
Patient weight based on Finnish real-life
distribution
20,178,296 4,416,134 16,067,093 6,746,326
Annual adherence drop 10% after 1st
year
19,033,150 2,038,510 12,049,898 4,040,788
No screening costs 19,822,386 4,631,370 16,280,555 6,961,207
Time horizon 3 years 19,875,290 - 1,282,280 7,314,798 437,136
Fingolimod utilization: 14 28-tablet
packs during the 1st year, 13 packs
thereafter
19,995,689 4,930,645 16,249,701 7,194,456
Natalizumab utilization: 14
administrations during the 1st year,
13 administrations thereafter
19,995,689 4,598,742 19,951,070 7,669,207
Cost of natalizumab administration
€934.50
19,995,689 4,598,742 24,645,460 8,608,085
Cost of natalizumab administration
€373.00
19,995,689 4,598,742 17,098,900 7,098,773
All cost inputs -20% 15,996,551 3,678,993 12,999,761 5,543,147
All cost inputs ?20% 23,994,826 5,518,490 19,499,641 8,314,720
24% of cladribine users assumed to
switch to ﬁngolimod on the fourth
year
21,548,433 3,045,997 14,696,957 5,376,189
Direct costs only 19,890,489 4,541,817 15,650,099 6,763,473
Direct costs only, no travelling costs 19,823,970 4,514,509 15,145,366 6,640,680
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fingolimod was €4580 less costly per patient and
€1,282,280 less costly in the overall population
compared to cladribine tablets.
As in all health economic modelling, the
results of the present study are subject to
uncertainty. Although progressive multifocal
leukoencephalopathy (PML) is a severe adverse
event associated with natalizumab, and to a
lesser extent also with other MS drugs [48], the
treatment-related risk of PML in MS is still very
low [49]. Due to the high uncertainty in the
PML incidence data in clinical trials, it was not
considered in our analyses. The total cost of
natalizumab, therefore, can be an
underestimate.
In addition, we did not include MS relapses
in the analysis, despite their impact on costs
based on Finnish real-world evidence [16], due
to the lack of sufficiently comparable evidence
regarding relapse incidence. However, as the
cost of relapse is likely to be relatively low
(€1316 for events not requiring hospitalization
and €5619 for events requiring hospitalization
[16]) compared to the total costs observed in the
present study, the impact of relapses as AEs on
the results would most likely have been low.
The inclusion of decreased persistence over
time resulted in a decrease in the drug-acquisi-
tion and administration costs, and the decrease
was more profound in drugs that were used for
the whole 4 years, i.e. fingolimod and natal-
izumab. As the present analysis considered only
drug-related costs, decreased persistence nar-
rowed the cost gap between cladribine and
comparators, although cladribine tablets
remained the most affordable.
In addition, persistence does not only affect
costs but also the treatment effects, which were
outside the scope of this study. Therefore, the
interpretation of the effect of persistence on the
results does not reflect cost-effectiveness results.
Furthermore, the inclusion of costs related to
disease progression (disability) could have had a
significant impact on the total costs (see, e.g.,
[16]). However, their inclusion would have been
complicated and most likely given unreliable
results, as there are no direct randomised com-
parisons between cladribine tablets, fingolimod
and natalizumab. However, cladribine tablets
have demonstrated a comparable efficacy with
other DMDs for highly active disease in recent
indirect comparison analyses [50–52]. Thus,
speculatively, the inclusion of treatment effects
could have even increased the affordability of
cladribine tablets.
In systematic reviews, indirect comparisons,
health economic analyses and models, system-
atic reporting is especially important [21, 50].
PICO is commonly applied in, e.g., evidence
synthesis and Finnish current care treatment
guidelines. Here, we applied an extended ver-
sion of PICO (PICOSTEPS) [16, 21] in order to
improve the readability of CAM and these
results, and to present the core components of
CAM. PICOSTEPS has previously been success-
fully applied in various health economic eval-
uations [16, 21–23, 46, 47, 53–56], and in real-
world data-based predictive cost-effectiveness
and cost–benefit assessments of first-line RRMS
treatments [16].
In Finland, the prices of hospital-adminis-
tered drugs may be confidentially negotiated
(tendered) by the hospital, which may lead to
lower drug costs paid by the hospital than the
official drug price list suggests. On the other
hand, this may lead to an underestimation of
administration costs. As some hospitals’ price
tariff lists provide a single cost per administra-
tion visit (i.e. including both the administration
and the drug), the proportion of administration
may be higher than that observed by subtract-
ing the official list price from the total cost of
the administration visit.
The present study did not address the effec-
tiveness or cost-effectiveness of the treatments,
and nor did it include costs related to effec-
tiveness. This was the main limitation of the
study. Therefore, further studies are needed to
provide this information, and to gain a more
complete understanding of the potential of the
different treatments.
CONCLUSION
Among patients with highly active relapsing
MS, cladribine tablets are projected to robustly
save expected drug-associated costs in compar-
ison to fingolimod, natalizumab and their mix
in Finland.
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